Weekly SC administration of Leqembi reduced amyloid plaque more than six biweekly IV administration. Credit: MICROGEN IMAGES/SCIENCE PHOTO LIBRARY via Getty Images.

BioArctic and Eisai have announced new positive Phase III data on the subcutaneous formulation for Leqembi (lecanemab-irmb). 

The companies presented the data at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, US, between 24 and 27 October. 

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Phase III trial (NCT03887455) is an open-label extension (OLE) substudy of the Clarity AD trial which compared the subcutaneous (SC) administration of Leqembi with intravenous infusion (IV). Data revealed that weekly SC administration of the drug resulted in a 14% greater reduction of amyloid plaques as measured by positron emission tomography (PET) at six months compared to biweekly IV administration.  

Incidence of amyloid-related imaging abnormalities (ARIA) with SC administration was found to be similar to IV, indicating that the SC formulation does not lead to an increased risk of ARIA. 

Leqembi is a monoclonal antibody that targets and reduces insoluble amyloid-beta (Aβ) forms in the brain. It is the first and only approved treatment that has demonstrated a reduction in the rate of disease progression in patients with Alzheimer’s.  

Leqembi was awarded full traditional approval in the US in July 2023, as well as in Japan in September 2023. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

GlobalData’s consensus forecast projects global sales for Leqembi to exceed $54bn by 2029. 

Leqembi faces competition from Eli Lilly’s donanemab, a similar monoclonal antibody targeting amyloid beta plaques, with GlobalData predicting sales exceeding $5.8bn in 2029. However, the FDA rejected Eli Lilly’s bid for accelerated approval of donanemab in January 2023, leaving Leqembi as the leading drug in this space.

GlobalData is the parent company of Clinical Trials Arena. 

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact